ERBB2 and breast carcinoma: Previous reports showed efficacy and tolerability of S36835 in the treatment of Eμ-Myc lymphoma21 and triple negative (ER/PR/ERBB2 negative) breast cancer xenografts26, the latter suggesting a favourable pharmacokinetic profile, also in solid tumour.